News

Metaverse Will Bring $15B Annually To Gulf Economies By 2030

The travel and tourism industries alone will gain $3.2 billion once the virtual universe reaches its full potential.

Published

1 year ago

December 8, 2022

metaverse will bring $15 billion to gulf economies by 2030

Saudi Arabia and the United Arab Emirates are already heavily invested in the development of the Metaverse, and the tech startups are playing a pivotal role in its construction. According to a recent report compiled by Strategy& Middle East, that investment will likely pay off to the tune of a cool $15 billion in annual revenue by 2030.

“The projections assessed growth in the component technologies, platforms, hardware, and software, as well as the economic contribution of new metaverse applications such as content creation, shopping, and so on,” says Tony G. Karam, partner at Strategy& Middle East.

Out of the seven Emirates, Dubai is emerging as the pre-eminent metaverse economy. Experts predict that the region’s digital strategy will bring a $4 billion boost to GDP, with 40,000 new jobs created in the process. The UAE as a whole has embraced Web3.0 enthusiastically and recently established the first metaverse incubator.

Meanwhile, in Saudi Arabia, NEOM — a $500 billion futuristic metropolis on the Red Sea — will also build a parallel digital version of its cityscape, enabling people to coexist in both the real world and the Metaverse simultaneously.

Also Read: The UAE Has Launched A Program To Assist 100 Startups

“The Metaverse holds a world of possibilities that extends beyond next-generation gaming and internet-based home buying or shopping. It will change how we work, transact, plan, design, build, shop, recreate, travel, and live. In a regional context, the Metaverse’s potential to energize and transform key sectors in the Gulf Cooperation Council (GCC) countries is enormous,” says Dany Karam, partner at Strategy& Middle East.

Breaking down Strategy&’s predicted annual raise in GDP reveals the following figures:

Saudi Arabia: $7.6 billion
UAE: $3.3 billion
Qatar: $1.6 billion
Kuwait: $ 1 billion
Oman: $0.8 billion
Bahrain: $0.4 billion

Although the Metaverse is still relatively unknown to the general public, experts believe that in the near future, a thriving digital tourism sector will emerge, with tours to famous UNESCO World Heritage Sites, concerts, festivals and sports events all having their own digital versions.

News

Orchid Plans To Find Out What’s Wrong With You Before You’re Born

According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.

Published

7 hours ago

May 7, 2024

Nour Nasir

Orchid

Each day, around 400,000 babies are welcomed into the world. However, among those, a growing number will experience some kind of birth defect or inherited disease.

Noor Siddiqui, CEO of Orchid, hopes to “mitigate” unpleasant genetic surprises using genome sequencing technology to reveal a wealth of genetic information on which newborns will grow into healthy adults.

Until 2019, IVF specialists had access to under 1% of the human genome. The tests, called PGT-A and PGT-M, scanned a mere 1,000 data points in a genome comprising around 3 billion bases, offering a very limited dataset compared to the technology used by Orchid.

“Our chromosomes are like chapters in a book that make up the table of contents.” Explained Siddiqui. “[PGT-A and PGT-M tests] only examine the table of contents, whereas what Orchid is doing is like a spellcheck on the entire book.” Orchid’s genome sampling technology assesses “100 times the data, covering many more conditions.” In essence, an Orchid report covers three categories of common genetic issues: monogenic disorders, polygenic conditions, and de-novo mutations.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Orchid’s technology raises many questions. Aside from the obvious ethical concerns, data privacy is the most obvious potential issue with the tests. Noor Siddiqui is keen to alleviate any concerns: “No data at Orchid is ever sold to any third parties. Parents are in complete control of their data. If they want to delete the data, we’re happy to delete it off of our servers. If they want to export the data, they can export the data. And if they want us to re-analyze the data, we can re-analyze the data”.

Compared to a lifetime of medical bills, gene therapy, and suffering, Orchid’s genome screening report has the potential to change the future lives of thousands of newborns worldwide.